Posted by Michael Wonder on 06 Aug 2021
Actuate Therapeutics announces FDA fast track designation for 9-ING-41 for treatment of pancreatic cancer
5 August 2021 - Actuate Therapeutics today announced that the U.S. FDA has granted fast track designation for 9-ING-41 for treatment of patients with pancreatic cancer.
9-ING-41 is Actuate's proprietary small molecule glycogen synthase kinase-3 beta inhibitor which is being developed for adults and children with advanced refractory cancers.
